These data, presented at the American Diabetes Association 79th Scientific Sessions, San Francisco, USA, and simultaneously published in The Lancet Diabetes and Endocrinology, showed a 47% reduction with Farxiga in the relative risk of the composite renal-specific outcome of kidney function decline (sustained ≥40% decrease in estimated glomerular filtration rate [eGFR] to
CSL reveals top-line outcome from Phase three AEGIS-II trial of CSL112
AstraZeneca invests USD300m to expand US manufacturing for cell therapy
Innovent Biologics announces CFO transition
Cardio Diagnostics appoints Dr Vimal Ramjee as Strategic Advisor
Acticor Biotech reports positive ACTIMIS clinical study results in Lancet Neurology Journal
Sarepta Therapeutics commences Phase 3 clinical study of SRP-9003 for LGMD2E